Literature DB >> 32961553

Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes.

Yasunobu Nagata1,2, Ran Zhao3, Hassan Awada1, Cassandra M Kerr1, Inom Mirzaev1, Sunisa Kongkiatkamon1, Aziz Nazha4, Hideki Makishima5, Tomas Radivoyevitch3, Jacob G Scott1, Mikkael A Sekeres4, Brian P Hobbs3, Jaroslaw P Maciejewski1.   

Abstract

Morphologic interpretation is the standard in diagnosing myelodysplastic syndrome (MDS), but it has limitations, such as varying reliability in pathologic evaluation and lack of integration with genetic data. Somatic events shape morphologic features, but the complexity of morphologic and genetic changes makes clear associations challenging. This article interrogates novel clinical subtypes of MDS using a machine-learning technique devised to identify patterns of cooccurrence among morphologic features and genomic events. We sequenced 1079 MDS patients and analyzed bone marrow morphologic alterations and other clinical features. A total of 1929 somatic mutations were identified. Five distinct morphologic profiles with unique clinical characteristics were defined. Seventy-seven percent of higher-risk patients clustered in profile 1. All lower-risk (LR) patients clustered into the remaining 4 profiles: profile 2 was characterized by pancytopenia, profile 3 by monocytosis, profile 4 by elevated megakaryocytes, and profile 5 by erythroid dysplasia. These profiles could also separate patients with different prognoses. LR MDS patients were classified into 8 genetic signatures (eg, signature A had TET2 mutations, signature B had both TET2 and SRSF2 mutations, and signature G had SF3B1 mutations), demonstrating association with specific morphologic profiles. Six morphologic profiles/genetic signature associations were confirmed in a separate analysis of an independent cohort. Our study demonstrates that nonrandom or even pathognomonic relationships between morphology and genotype to define clinical features can be identified. This is the first comprehensive implementation of machine-learning algorithms to elucidate potential intrinsic interdependencies among genetic lesions, morphologies, and clinical prognostic in attributes of MDS.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2020        PMID: 32961553      PMCID: PMC7702479          DOI: 10.1182/blood.2020005488

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  34 in total

Review 1.  Classification and prognostic evaluation of myelodysplastic syndromes.

Authors:  Mario Cazzola; Matteo G Della Porta; Erica Travaglino; Luca Malcovati
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

2.  Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53.

Authors:  Rashmi Kanagal-Shamanna; Carlos E Bueso-Ramos; Bedia Barkoh; Gary Lu; Sa Wang; Guillermo Garcia-Manero; Saroj Vadhan-Raj; Daniela Hoehn; L Jeffrey Medeiros; C Cameron Yin
Journal:  Cancer       Date:  2011-10-28       Impact factor: 6.860

3.  Integrating genomic signatures for treatment selection with Bayesian predictive failure time models.

Authors:  Junsheng Ma; Brian P Hobbs; Francesco C Stingo
Journal:  Stat Methods Med Res       Date:  2016-11-01       Impact factor: 3.021

4.  Bayesian predictive modeling for genomic based personalized treatment selection.

Authors:  Junsheng Ma; Francesco C Stingo; Brian P Hobbs
Journal:  Biometrics       Date:  2015-11-17       Impact factor: 2.571

5.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data.

Authors:  Kai Wang; Mingyao Li; Hakon Hakonarson
Journal:  Nucleic Acids Res       Date:  2010-07-03       Impact factor: 16.971

6.  Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.

Authors:  J Broséus; T Alpermann; M Wulfert; L Florensa Brichs; S Jeromin; E Lippert; M Rozman; F Lifermann; V Grossmann; T Haferlach; U Germing; E Luño; F Girodon; S Schnittger
Journal:  Leukemia       Date:  2013-04-18       Impact factor: 11.528

Review 7.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

8.  Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms.

Authors:  Chantana Polprasert; Isabell Schulze; Mikkael A Sekeres; Hideki Makishima; Bartlomiej Przychodzen; Naoko Hosono; Jarnail Singh; Richard A Padgett; Xiaorong Gu; James G Phillips; Michael Clemente; Yvonne Parker; Daniel Lindner; Brittney Dienes; Eckhard Jankowsky; Yogen Saunthararajah; Yang Du; Kevin Oakley; Nhu Nguyen; Sudipto Mukherjee; Caroline Pabst; Lucy A Godley; Jane E Churpek; Daniel A Pollyea; Utz Krug; Wolfgang E Berdel; Hans-Ulrich Klein; Martin Dugas; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Satoru Miyano; Kenichi Yoshida; Seishi Ogawa; Carsten Müller-Tidow; Jaroslaw P Maciejewski
Journal:  Cancer Cell       Date:  2015-04-23       Impact factor: 31.743

9.  Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes.

Authors:  Yasunobu Nagata; Hideki Makishima; Cassandra M Kerr; Bartlomiej P Przychodzen; Mai Aly; Abhinav Goyal; Hassan Awada; Mohammad Fahad Asad; Teodora Kuzmanovic; Hiromichi Suzuki; Tetsuichi Yoshizato; Kenichi Yoshida; Kenichi Chiba; Hiroko Tanaka; Yuichi Shiraishi; Satoru Miyano; Sudipto Mukherjee; Thomas LaFramboise; Aziz Nazha; Mikkael A Sekeres; Tomas Radivoyevitch; Torsten Haferlach; Seishi Ogawa; Jaroslaw P Maciejewski
Journal:  Nat Commun       Date:  2019-11-26       Impact factor: 17.694

10.  MYH9-related disease: five novel mutations expanding the spectrum of causative mutations and confirming genotype/phenotype correlations.

Authors:  Daniela De Rocco; Barbara Zieger; Helen Platokouki; Paula G Heller; Annalisa Pastore; Roberta Bottega; Patrizia Noris; Serena Barozzi; Ana C Glembotsky; Helen Pergantou; Carlo L Balduini; Anna Savoia; Alessandro Pecci
Journal:  Eur J Med Genet       Date:  2012-10-30       Impact factor: 2.708

View more
  15 in total

1.  Have we reached a molecular era in myelodysplastic syndromes?

Authors:  Maria Teresa Voso; Carmelo Gurnari
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDS.

Authors:  Oscar E Brück; Susanna E Lallukka-Brück; Helena R Hohtari; Aleksandr Ianevski; Freja T Ebeling; Panu E Kovanen; Soili I Kytölä; Tero A Aittokallio; Pedro M Ramos; Kimmo V Porkka; Satu M Mustjoki
Journal:  Blood Cancer Discov       Date:  2021-03-22

3.  Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML.

Authors:  Raphael Itzykson; Thomas Cluzeau; Matthieu Duchmann; Orianne Wagner-Ballon; Thomas Boyer; Meyling Cheok; Elise Fournier; Estelle Guerin; Laurène Fenwarth; Bouchra Badaoui; Nicolas Freynet; Emmanuel Benayoun; Daniel Lusina; Isabel Garcia; Claude Gardin; Pierre Fenaux; Cécile Pautas; Bruno Quesnel; Pascal Turlure; Christine Terré; Xavier Thomas; Juliette Lambert; Aline Renneville; Claude Preudhomme; Hervé Dombret
Journal:  Leukemia       Date:  2021-10-06       Impact factor: 11.528

Review 4.  Precision Medicine in Myeloid Malignancies: Hype or Hope?

Authors:  Shristi Upadhyay Banskota; Nabin Khanal; Rosalyn I Marar; Prajwal Dhakal; Vijaya Raj Bhatt
Journal:  Curr Hematol Malig Rep       Date:  2022-08-16       Impact factor: 4.213

5.  Towards artificial intelligence-driven pathology assessment for hematological malignancies.

Authors:  Olivier Elemento
Journal:  Blood Cancer Discov       Date:  2021-03-22

Review 6.  Prognostic mutation constellations in acute myeloid leukaemia and myelodysplastic syndrome.

Authors:  Ilaria Iacobucci; Charles G Mullighan
Journal:  Curr Opin Hematol       Date:  2021-03-01       Impact factor: 3.284

Review 7.  TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics.

Authors:  Yihong Guan; Metis Hasipek; Anand D Tiwari; Jaroslaw P Maciejewski; Babal K Jha
Journal:  Semin Hematol       Date:  2020-12-28       Impact factor: 3.851

Review 8.  Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms.

Authors:  Laura Palomo; Pamela Acha; Francesc Solé
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

Review 9.  Application of Single-Cell Approaches to Study Myeloproliferative Neoplasm Biology.

Authors:  Daniel Royston; Adam J Mead; Bethan Psaila
Journal:  Hematol Oncol Clin North Am       Date:  2021-04       Impact factor: 3.722

10.  TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes.

Authors:  Carmelo Gurnari; Simona Pagliuca; Yihong Guan; Vera Adema; Courtney E Hershberger; Ying Ni; Hassan Awada; Sunisa Kongkiatkamon; Misam Zawit; Diego F Coutinho; Ilana R Zalcberg; Jae-Sook Ahn; Hyeoung-Joon Kim; Dennis Dong Hwan Kim; Mark D Minden; Joop H Jansen; Manja Meggendorfer; Claudia Haferlach; Babal K Jha; Torsten Haferlach; Jaroslaw P Maciejewski; Valeria Visconte
Journal:  Blood Adv       Date:  2022-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.